Lipid Nanoparticle-mRNA Vaccines Against Chlamydia psittaci: Evidence and Implications from Preclinical Models

Study Background and Research Question

Chlamydia psittaci is a zoonotic pathogen responsible for psittacosis, a disease that can manifest as severe pulmonary and systemic illness in both birds and humans. Its ability to cross species barriers, cause latent infections, and evade eradication through standard antibiotic regimens presents ongoing public health and agricultural challenges. With increasing case detection, driven by advances in clinical diagnostics, the need for preventive strategies such as effective vaccines has become more urgent. However, conventional vaccine platforms have faced limitations in both safety and efficacy for intracellular pathogens like C. psittaci. The reference study (Wang et al., 2025) addresses a crucial research question: Can a lipid nanoparticle (LNP)-encapsulated mRNA vaccine encoding the C. psittaci major outer membrane protein (MOMP) induce protective immune responses and reduce pathogen burden in a susceptible mammalian model?

Key Innovation from the Reference Study

The central innovation of Wang et al., 2025 lies in the construction and preclinical assessment of a non-replicating mRNA vaccine encoding MOMP, encapsulated in LNPs. This platform leverages the advantages of mRNA vaccine technology—rapid design, non-integrative expression, and the potential for immune modulation via nucleotide modifications. By targeting MOMP, a well-conserved and immunogenic surface protein, the study aims to elicit both humoral and cellular immunity specific to C. psittaci. The use of LNPs as delivery vehicles further addresses mRNA instability and enables efficient cellular uptake, which are critical for in vivo translation and antigen presentation. Notably, the study explicitly evaluates the vaccine’s impact on pathogen load and inflammatory cytokine profiles in a relevant mouse model, providing a rigorous test of protective efficacy.

Methods and Experimental Design Insights

The vaccine mRNA was synthesized in vitro using a transcription system designed for high-fidelity, capped, and non-replicating transcripts. The resulting mRNA encoded a codon-optimized form of the C. psittaci MOMP antigen. After purification, mRNA was encapsulated in LNPs formulated to optimize particle size, morphology, and cytocompatibility. The LNP-mRNA complexes were characterized using dynamic light scattering and electron microscopy, ensuring uniformity and suitability for in vivo delivery.

In vitro, HeLa cells were transfected with the LNP-mRNA vaccine, and expression of MOMP was confirmed by western blot. For in vivo assessment, groups of BALB/c mice were immunized with the LNP-Opt-mRNA vaccine and subsequently challenged with C. psittaci. Key endpoints included pathogen load in lung tissue (quantified by PCR and histopathology), cytokine levels (interferon-γ, TNF-α, IL-6), and immunofluorescence detection of chlamydial antigens. The experimental design allowed for direct comparison between vaccinated and control (PBS) groups, with both immunogenicity and protective efficacy assessed.

Protocol Parameters

• Antigen selection: Codon-optimized mRNA encoding C. psittaci MOMP, non-replicating.
• In vitro mRNA synthesis: Enzymatic transcription using a cap analog and modified nucleotides for stability and reduced immunogenicity (as supported by recent mRNA vaccine technology trends).
• Lipid nanoparticle formulation: Precise control of particle size and morphology for optimal delivery; detailed characterization by electron microscopy and DLS.
• Mouse immunization: BALB/c mice, schedule and dosage as per the reference study, with post-vaccination challenge to assess protection.
• Assessment endpoints: Pathogen burden (PCR/histology), lung cytokine concentrations, humoral and cellular immune responses.

Core Findings and Why They Matter

The study demonstrates that mice immunized with the LNP-mRNA vaccine encoding MOMP exhibited robust immune responses and significant protection against C. psittaci challenge. Key findings include:

• Strong induction of both humoral (antibody-mediated) and cellular immune responses.
• Marked reduction in pulmonary C. psittaci load as measured by PCR and histopathology.
• Effective expression of recombinant MOMP in vitro, confirming the translation potential of the delivered mRNA.
• Decreased concentrations of pro-inflammatory cytokines (interferon-γ, TNF-α, IL-6) in lung tissue of vaccinated mice, indicative of reduced pathological inflammation.
• Histological evidence for reduced chlamydial infection and pathogen shedding in immunized animals.

These results collectively validate the use of LNP-mRNA vaccines for controlling C. psittaci infection, and by extension, other intracellular respiratory pathogens. The study also underscores the translational value of immune response reduction by modified nucleotides, a strategy now widely adopted in mRNA vaccine development (Wang et al., 2025).

Comparison with Existing Internal Articles

The findings of Wang et al. are in alignment with several technical analyses and protocol case studies. For instance, LNP-mRNA Vaccine Targeting C. psittaci MOMP: Preclinical Insights offers a summary of the same preclinical model, highlighting the potential of LNP-encapsulated mRNA for respiratory zoonoses. Further, articles such as HyperScribe All in One mRNA Synthesis Kit Plus 1: Applied Protocols and Innovations and HyperScribe All in One mRNA Synthesis Kit: Precision & Evidence discuss the workflow and technological underpinnings relevant to producing ARCA-capped, immune-evasive mRNA, with direct applicability to vaccine design, in vitro translation of modified mRNA, and RNA interference (RNAi) experiments. These internal resources reinforce the value of streamlined, reproducible mRNA synthesis workflows and the necessity of robust cap analog and nucleotide modifications for translational efficiency and immune response reduction.

Limitations and Transferability

While the preclinical results are promising, several limitations must be acknowledged. The study is limited to a single animal model (BALB/c mice), and the immunization protocol is specific to the experimental context; extrapolation to other species or to human clinical settings requires further validation. The challenge dose and pathogen strain may not fully capture the diversity of real-world zoonotic exposures. Additionally, while the vaccine was effective in reducing cytokine-mediated inflammation, the long-term durability of protection and the potential for immune memory were not addressed. Nevertheless, the protocol and findings provide a valuable technical benchmark for researchers exploring RNA vaccine development against intracellular pathogens.

Why this cross-domain matters, maturity, and limitations

The demonstrated efficacy of mRNA vaccines for a bacterial intracellular pathogen such as C. psittaci opens new avenues beyond viral targets, traditionally the mainstay for mRNA vaccine platforms. This cross-domain innovation—adapting RNA technology for bacterial vaccine development—highlights the versatility and growing maturity of in vitro transcription mRNA synthesis with 5mCTP and ψUTP, as well as the importance of delivery systems that can target respiratory tissues. However, further work is needed to assess scalability, safety, and efficacy in non-rodent models and ultimately in human populations. Current findings provide a foundation but not yet a complete solution for cross-domain translation.

Research Support Resources

For researchers seeking to replicate or extend these findings, robust and reproducible mRNA synthesis is essential. The HyperScribe™ All in One mRNA Synthesis Kit Plus 1 (ARCA, 5mCTP, ψUTP, T7, poly(A)) (SKU K1064) from APExBIO supports ARCA-capped, nucleotide-modified, and polyadenylated mRNA synthesis suitable for workflows in RNA vaccine development, in vitro translation, and immune response modulation. Its integrated protocol facilitates efficient mRNA production, aligning with best practices outlined in recent LNP-mRNA vaccine studies. Researchers can leverage such resources to enable advanced applications in vaccine and RNAi research with enhanced reliability and translational potential.